Encycle Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $80M

Encycle Therapeutics General Information

Description

Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's drugs are generated by several scaffolds that are membrane-permeable and orally bioavailable products thereby, enabling patients to get cured of inflammatory bowel disease and other inflammatory disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 101 College Street
  • Suite 314
  • Toronto, Ontario M5G 1L7
  • Canada

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Encycle Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 22-Oct-2019 $80M 00.000 0000 Completed Generating Revenue
5. Corporate 01-Nov-2017 00000 00.000 Completed Generating Revenue
4. Early Stage VC 30-Sep-2015 00.000 00.000 Completed Startup
3. Early Stage VC 16-Jun-2015 00000 00.000 Completed Startup
2. Grant 17-Nov-2014 $2.5M Completed Startup
1. Early Stage VC 11-Nov-2014 $2.5M $2.5M Completed Startup
To view Encycle Therapeutics’s complete valuation and funding history, request access »

Encycle Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's dru
Drug Discovery
Toronto, Canada
6 As of 2015
00.000
0000 0000-00-00
000000&0 00.000

000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
0000 000000000
Boston, MA
000 As of 0000
00000
000000000 00000

000000

usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim venia
0000 000000000
Watertown, MA
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Encycle Therapeutics Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA 000 00000 000000000 00000
Aileron Therapeutics Formerly VC-backed Watertown, MA 0 00000 000000000 00000
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
Apeptico Venture Capital-Backed Vienna, Austria 00.00 0000000000 00.00
Oncorus Formerly VC-backed Andover, MA 00 00000 000000000000 00000
You’re viewing 5 of 15 competitors. Get the full list »

Encycle Therapeutics Patents

Encycle Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2967750-A1 Solid phase synthesis of cyclic amino acid molecules Inactive 19-Nov-2014 0000000000
EP-3221335-A1 Solid phase synthesis of cyclic amino acid molecules Inactive 19-Nov-2014 0000000000
EP-3221335-A4 Solid phase synthesis of cyclic amino acid molecules Inactive 19-Nov-2014 0000000000 0
US-20170320908-A1 Solid phase synthesis of cyclic amino acid molecules Inactive 19-Nov-2014 C07K1/1077

Encycle Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Encycle Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Accel-Rx Accelerator/Incubator Minority 000 0000 000000 0
BDC Capital Growth/Expansion Minority 000 0000 000000 0
CQDM Not-For-Profit Venture Capital Minority 000 0000 000000 0
MaRS Investment Accelerator Fund Venture Capital Minority 000 0000 000000 0
Merck & Co. Corporation 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Encycle Therapeutics FAQs

  • When was Encycle Therapeutics founded?

    Encycle Therapeutics was founded in 2012.

  • Who is the founder of Encycle Therapeutics?

    Andrei Yudin Ph.D is the founder of Encycle Therapeutics.

  • Where is Encycle Therapeutics headquartered?

    Encycle Therapeutics is headquartered in Toronto, Canada.

  • What is the size of Encycle Therapeutics?

    Encycle Therapeutics has 6 total employees.

  • What industry is Encycle Therapeutics in?

    Encycle Therapeutics’s primary industry is Drug Discovery.

  • Is Encycle Therapeutics a private or public company?

    Encycle Therapeutics is a Private company.

  • What is the current valuation of Encycle Therapeutics?

    The current valuation of Encycle Therapeutics is 0000.

  • What is Encycle Therapeutics’s current revenue?

    The current revenue for Encycle Therapeutics is 000000.

  • How much funding has Encycle Therapeutics raised over time?

    Encycle Therapeutics has raised $5.99M.

  • Who are Encycle Therapeutics’s investors?

    Accel-Rx, BDC Capital, CQDM, MaRS Investment Accelerator Fund, and Merck & Co. are 5 of 9 investors who have invested in Encycle Therapeutics.

  • Who are Encycle Therapeutics’s competitors?

    Rhythm Pharmaceuticals, Aileron Therapeutics, Alnylam Pharmaceuticals, Apeptico, and Oncorus are some of the 15 competitors of Encycle Therapeutics.

  • When was Encycle Therapeutics acquired?

    Encycle Therapeutics was acquired on 22-Oct-2019.

  • Who acquired Encycle Therapeutics?

    Encycle Therapeutics was acquired by Zealand Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »